Related Experiment Video
Updated: Jun 5, 2025
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
299
Tirzepatide for overweight and obesity management
Malak Hamza1,2, Dimitris Papamargaritis1,2,3, Melanie J Davies1,2
1Diabetes Research Centre, University of Leicester, Leicester, UK.
Expert Opinion on Pharmacotherapy
|December 5, 2024
Summary
Tirzepatide, a dual GLP-1/GIP agonist, offers significant weight loss and improves obesity-related conditions. Its safety profile is comparable to GLP-1 receptor agonists, marking a new treatment era.
Area of Science:
- Pharmacology
- Endocrinology
- Obesity Medicine
Background:
- Tirzepatide is a novel dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
- It is administered once weekly at doses of 5, 10, and 15 mg.
Purpose of the Study:
- To review the global Phase 3 SURMOUNT program for tirzepatide in chronic weight management.
- To discuss findings from regional trials (SURMOUNT-CN, SURMOUNT-J) and studies on obesity-related complications (SYNERGY-NASH, SURMOUNT-OSA, SUMMIT).
- To explore clinical implications, prescribing considerations, and future research directions for tirzepatide in obesity.
Main Methods:
- Systematic review of published data from PubMed, clinicaltrials.gov, conference abstracts, and manufacturer's website.
- Analysis of safety and efficacy data from Phase 3 SURMOUNT trials and related studies.
Main Results:
- Tirzepatide enables significant weight loss (≥20%) and demonstrates a favorable safety profile similar to GLP-1 receptor agonists.
- Clinically meaningful improvements were observed in obesity-related comorbidities, including sleep apnea, NASH, and HFpEF, and diabetes prevention.
- Ongoing trials are evaluating long-term safety, efficacy, cardiovascular outcomes, and cost-effectiveness.
Conclusions:
- Tirzepatide represents a significant advancement in the treatment of overweight and obesity.
- It offers substantial weight reduction and benefits for multiple obesity-related health issues.
- Further research will elucidate its long-term impact and economic value in managing obesity and T2D.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:24Obesity
374
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
374
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:26Psychosis: Goals of Pharmacotherapy
103
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
103